1.
Haematologica
; 109(7): 2364-2367, 2024 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38186348
Assuntos
Transfusão de Linfócitos , Humanos , Masculino , Neoplasias Embrionárias de Células Germinativas/terapia , Neoplasias Embrionárias de Células Germinativas/patologia , Neoplasias Embrionárias de Células Germinativas/imunologia , Neoplasias Embrionárias de Células Germinativas/diagnóstico , Linfócitos T/imunologia , Linfócitos T/metabolismo , Sarcoma/terapia , Sarcoma/patologia , Sarcoma/imunologia , Resultado do Tratamento , Antígenos de Neoplasias/imunologia , Adulto
2.
Rev Med Suisse
; 9(387): 1080-2, 1084-6, 2013 May 22.
Artigo
em Francês
| MEDLINE
| ID: mdl-23757915
RESUMO
Antibody-drug conjugates (ADCs) are therapeutic agents combining the specificity of a monoclonal antibody for a target antigen with the delivery of a highly potent cytotoxic drug. Their development has been hampered by numerous problems, which are now better identified and partially solved. This finally led to the recent approval of brentuximab vedotin by the US Food and Drug Administration (FDA), as well as in Europe. Trastuzumab emtasin has also been very recently approved by the FDA. Over 20 other ADCs are being investigated, with two of them (inotuzumab ozogamicin and gemtuzumab ozogamicin) in late stage of clinical evaluation. In the near future, ADCs may provide a powerful and selective treatment option for cancer patient.